聚乙二醇化赛妥珠单抗成功治疗与寻常型银屑病相关的慢性前葡萄膜炎。
Successful Certolizumab Pegol Treatment of Chronic Anterior Uveitis Associated with Psoriasis Vulgaris.
作者信息
Yamaguchi Keiko, Hayashi Takaaki, Takahashi Genichiro, Momose Mami, Asahina Akihiko, Nakano Tadashi
机构信息
Department of Ophthalmology, Katsushika Medical Center, The Jikei University School of Medicine, Tokyo, Japan.
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
出版信息
Case Rep Ophthalmol. 2018 Dec 13;9(3):499-503. doi: 10.1159/000495655. eCollection 2018 Sep-Dec.
This report presents details on a 45-year-old male Japanese patient with chronic and refractory anterior uveitis associated with psoriasis vulgaris who was administered certolizumab pegol (CZP), which is an anti-tumor necrosis factor alpha (TNF-α) monoclonal antibody. Although CZP has only been formally approved for rheumatoid arthritis treatment in Japan, a clinical trial allowed us to assess CZP effectiveness in this patient. The grade 3+ anterior chamber inflammation (for both the cells and flare) observed at baseline improved to grade 0 at 3 months post-treatment. Dermatologically, the psoriasis area severity index (PASI) score was 25.4, while the body surface area (BSA) was 88% at baseline. At 3 months after treatment, the scores improved to 2.8 for PASI and less than 1% for BSA. After the treatment, remission has lasted for at least 9 months. No adverse events were seen during the CZP treatment. These findings suggest that CZP could be an effective therapeutic alternative in some refractory anterior uveitis patients with psoriasis vulgaris.
本报告详细介绍了一名45岁的日本男性患者，该患者患有与寻常型银屑病相关的慢性难治性前葡萄膜炎，接受了赛妥珠单抗（CZP）治疗，这是一种抗肿瘤坏死因子α（TNF-α）单克隆抗体。尽管在日本CZP仅被正式批准用于治疗类风湿性关节炎，但一项临床试验使我们能够评估CZP对该患者的有效性。基线时观察到的3级及以上前房炎症（细胞和房水闪辉）在治疗后3个月改善至0级。在皮肤病学方面，基线时银屑病面积严重程度指数（PASI）评分为25.4，而体表面积（BSA）为88%。治疗后3个月，PASI评分改善至2.8，BSA降至1%以下。治疗后，缓解期至少持续了9个月。在CZP治疗期间未观察到不良事件。这些发现表明，对于一些患有寻常型银屑病的难治性前葡萄膜炎患者，CZP可能是一种有效的治疗选择。
Zotero 插件